New hope for ulcerative colitis sufferers?
NCT ID NCT07232576
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tests a new drug called SHR-1139 in 20 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease. The treatment has two parts: a 12-week induction phase and a 48-week maintenance phase. The main goal is to see if the drug can improve symptoms by week 12.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital,Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
Conditions
Explore the condition pages connected to this study.